The pricing controversy surrounding Marathon Pharmaceuticals LLC's aborted launch of Emflaza (deflazacort) for Duchenne muscular dystrophy has also drawn critical attention to what Sen. Bernie Sanders and Rep. Elijah Cummings call the "unusual circumstances" of the drug's approval by FDA.
But analysis of FDA drug review documents shows that Emflaza's path to approval was not unprecedented. The corticosteroid for Duchenne...







